Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

18. Mai 2026 11:30 ET | Quelle: Upstream Bio

Upstream Bio Presents New Data from Phase 2 VIBRANT Trial of Verekitug Demonstrating Improvement in Asthma Symptom Control in Participants with CRSwNP and Comorbid Asthma at the ATS 2026 International Conference

– Verekitug led to statistically significant and clinically meaningful improvement in asthma symptom control as measured by the Asthma Control Questionnaire-6 (ACQ-6) in participants with CRSwNP and...
14. Mai 2026 16:30 ET | Quelle: Edesa Biotech, Inc.

Edesa Biotech Reports Fiscal 2nd Quarter 2026 Results

TORONTO, May 14, 2026 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory...
07. April 2026 17:30 ET | Quelle: Custom Market Insights

Global Anesthesia and Respiratory Devices Market Size/Share Worth USD 100.5 Billion by 2035 at a 5.8% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, SWOT Analysis)

Austin, TX, USA, April 08, 2026 (GLOBE NEWSWIRE) -- Healthcare Foresights has published a new research report titled “Anesthesia and Respiratory Devices Market Size, Trends and Insights By Product...
31. März 2026 16:20 ET | Quelle: Edesa Biotech, Inc.

Edesa Biotech Invited for Oral Showcase at Respiratory Innovation Summit

TORONTO, March 31, 2026 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory...
24. Februar 2026 09:15 ET | Quelle: Edesa Biotech, Inc.

Edesa Biotech Reports Additional Positive Results from Phase 3 Paridiprubart Study

Results in a population of 278 patients affirm statistically significant mortality reductionsBenefits observed across severity groups and in subjects with serious comorbiditiesCompany files...
13. Februar 2026 16:20 ET | Quelle: Edesa Biotech, Inc.

Edesa Biotech Reports Fiscal 1st Quarter 2026 Results

TORONTO, Feb. 13, 2026 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory...
10. Februar 2026 07:00 ET | Quelle: Regeneron Pharmaceuticals, Inc.

Regeneron Highlights Expanding Immunology Portfolio and Pipeline at AAAAI, Showcasing Novel Approaches to Treating Allergy

36 abstracts to be presented across Regeneron-invented therapies, including first-time Phase 3 presentations for two distinct investigational allergen-blocking antibodies for cat and birch allergies ...
29. Januar 2026 07:00 ET | Quelle: Kymera Therapeutics, Inc.

Kymera Therapeutics Announces First Patient Dosed in BREADTH Phase 2b Asthma Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader

Data from the BREADTH Phase 2b asthma trial is expected to be reported in late-2027 Data from the ongoing parallel BROADEN2 Phase 2b atopic dermatitis trial is expected to be reported by mid-2027 ...
23. Dezember 2025 01:00 ET | Quelle: Regeneron Pharmaceuticals, Inc.

Dupixent® (dupilumab) Approved in Japan for Children Aged 6 to 11 Years with Bronchial Asthma

Approval based on global Phase 3 program in children demonstrating Dupixent significantly reduced exacerbations (by 54% to 65%) and improved lung function (by 4.68% to 5.32%) compared to placebo ...
09. Dezember 2025 07:00 ET | Quelle: Lungpacer Medical USA Inc.

Lungpacer Achieves Commercial Milestone as Leading U.S. Hospital Performs First AeroPace® Procedures to Help Patients Liberate from Mechanical Ventilation

EXTON, Pa., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Lungpacer Medical, a leader in innovative respiratory care neurostimulation technologies, today announced that physicians at one of the nation’s largest...

Nächste Seite